MedTrace Logo

The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer

NCT02072512 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2014-02-26

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of goserelin plus fulvestrant 500mg comparing with goserelin plus anastrozole as first line endocrine therapy for pre- and perimenopausal HR+ advanced breast cancer.

Conditions

Interventions

DRUG

Fulvestrant

Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops

DRUG

Goserelin

goserelin 3.6mg subcutaneously every 28(± 3) days

DRUG

Anastrozole

Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops

DRUG

Goserelin

goserelin 3.6mg subcutaneously every 28(± 3) days

Sponsors & Collaborators

  • Hospital Affiliated to Military Medical Science, Beijing

    lead OTHER

Principal Investigators

  • Zefei Jiang, Ph.D · 307 Hospital of PLA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-11-30
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072512 on ClinicalTrials.gov